THRB-CVD20 Polypeptide and Polyclonal Antibody for Living-Cell Sorting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current commercial THRB antibodies are not suitable for flow cytometric sorting applications and lack the sensitivity and specificity needed to accurately recognize and identify THRB-positive living cells, limiting in-depth research on THRB functions.

Innovation Solution

A polypeptide fragment THRB-CVD20 is prepared using a specific method involving resin swelling, amino acid activation, protecting group removal, and purification, followed by the development of a polyclonal antibody with high sensitivity and specificity, enabling accurate identification and screening of THRB-positive cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If commercial THRB antibodies are used, then general THRB detection is possible, but flow cytometric sorting application and sensitivity/specificity for living cell identification are insufficient

Engineering Contradiction:

Improvesensitivity and specificityVSAvoidsuitability for flow cytometric sorting applications

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent modifies the antibody parameters by selecting a specific epitope region (amino acids 1-20 of THRB) and optimizing the immunogen construction parameters (carrier protein type, adjuvant concentration, immunization protocol) to achieve high sensitivity and specificity for flow cytometric sorting applications

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the THRB protein into a specific epitope region (amino acids 1-20) for antibody generation, separating this critical region from the rest of the protein structure to create an antibody with enhanced specificity for flow cytometric sorting

Inventive Principle:

Principle #1Segmentation

2Measurement precision

If existing THRB antibodies are used, then basic recognition is possible, but accurate identification and screening of THRB-positive living cells cannot be achieved

Engineering Contradiction:

Improveaccuracy of cell identificationVSAvoidreliability for living cell screening

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent performs preliminary actions by pre-characterizing the epitope sequence and pre-optimizing the immunogen construction before actual antibody generation, ensuring that the resulting antibody will reliably identify THRB-positive living cells with high accuracy

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent incorporates feedback mechanisms through iterative optimization of the immunization protocol and epitope selection based on preliminary binding assays, ensuring the antibody achieves reliable performance for living cell screening

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20250313609A1Polypeptide Fragment Thyroid Hormone Receptor BETA1 (THRB)-CVD20, and Polyclonal Antibody Prepared Using the Same and Use Thereof

Publication Date: 2025.10.09 BEIJING BIOSYNTHESIS BIOTECHNOLOGY CO LTD

AI summary

The present disclosure relates to the technical field of antibody engineering, and specifically provides a polypeptide fragment thyroid hormone receptor betal (THRB)-CVD20, and a polyclonal antibody prepared using the same and use thereof. The present disclosure provides a polypeptide fragment THRB-CVD20, wherein the polypeptide fragment has an amino acid sequence shown in SEQ ID NO: 1. The present disclosure further provides a preparation method of the polypeptide fragment and a polyclonal antibody prepared using the polypeptide fragment. In the present disclosure, the polyclonal antibody can accurately identify target cells due to high sensitivity and specificity, and can be further used to identify, identify, and screen the THRB.